CHMP recommends two new drugs for approval and rejects one

Japanese firm Kyowa Kirin's Parkinson's disease treatment was given a negative opinion at the council's meeting in July. Two other drugs were recommended for approval.

Photo: Rob Acket/EMA

The CHMP (Committee for Medicinal Products for Human use) did not have many drugs to consider in July.

The European Medicines Agency's expert panel only made recommendations in the case of three drugs. Of these, two were recommended for approval, whilst a negative opinion was adopted for the third.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs